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Abstract 
Background: Urticaria is a disorder affecting skin and mucosal tissues characterized by the occurrence of wheals, 
angioedema or both, the latter defining the urticaria-angioedema syndrome. It is estimated that 12–22% of the gen-
eral population has suffered at least one subtype of urticaria during life, but only a small percentage (estimated at 7.6–
16%) has acute urticaria, because it is usually self-limited and resolves spontaneously without requiring medical atten-
tion. This makes likely that its incidence is underestimated. The epidemiological data currently available on chronic 
urticaria in many cases are deeply discordant and not univocal, but a recent Italian study, based on the consultation of 
a national registry, reports a prevalence of chronic spontaneous urticaria of 0.02% to 0.4% and an incidence of 0.1–1.5 
cases/1000 inhabitants/year.
Methods: We reviewed the recent international guidelines about urticaria and we described a methodologic 
approach based on classification, pathophysiology, impact on quality of life, diagnosis and prognosis, differential 
diagnosis and management of all the types of urticaria.
Conclusions: The aim of the present document from the Italian Society of Allergology, Asthma and Clinical Immu-
nology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) is to 
provide updated information to all physicians involved in diagnosis and management of urticaria and angioedema.
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Background
Urticaria is a disorder affecting skin and mucosal tissues 
characterized by the occurrence of wheals, angioedema 
or both, the latter defining the urticaria-angioedema syn-
drome. The wheal is a skin lesion presenting with a central 
edema of variable size, surrounded by erythema and asso-
ciated to itching or, more rarely, feeling of warmth, that are 
transient, with spontaneous resolution in less than 24  h, 
and with no relics [1]. Under histological point of view, the 
wheal is characterized by edema of the superficial derma 
with a slight-moderate dilation of the vessels, in absence of 
wall damage and leucocytoclasy, with a perivascular gran-
ulocytic infiltrate of eosinophils and neutrophils with rare 
macrophages and lymphocytes. Angioedema is defined by 
a cutaneous and/or mucous lesion characterized by rapid 
onset of non-improntable and non-inflammatory edema of 
the deep dermis or subcutis, associated with pain or, less 
frequently, itching, with resolution within 72 h. Histologi-
cally, edema massively involves the deep dermis and the 
hypodermis, with a mostly perivasal granulocytic infil-
trate. Urticaria must be distinguished from other diseases 
in which the hives and angioedema, or clinically similar 
lesions, can present as symptoms. They include anaphy-
laxis, vasculitic urticaria (corresponding to a leukocyto-
clastic vasculitis), pigmentary urticaria (corresponding 
to a form of cutaneous mastocytosis), some cutaneous 
manifestations of ectoparasites, autoinflammatory syn-
dromes, bradykinin-mediated angioedema (such as for 
example, hereditary C1-inhibitor deficiency), Gleich’s syn-
drome (recurrent angioedema with eosinophilia) or Wells 
syndrome (granulomatous dermatitis with eosinophilia) 
[1]. Acute urticaria (AU) can occur in all ages, is usually 
self-limited and resolves spontaneously without requiring 
medical attention. This makes likely that its incidence is 
underestimated.
The aim of the present document from the Italian Soci-
ety of Allergology, Asthma and Clinical Immunology 
(SIAAIC) and the Italian Society of Allergological, Occu-
pational and Environmental Dermatology (SIDAPA) is to 
provide updated information to all physicians involved in 
diagnosis and management of urticaria and angioedema.
Classification of urticaria
Classification is based on duration of clinical manifesta-
tions and on causative agents.
AU is defined by a duration of < 6  weeks while for 
chronic urticaria (CU) the duration is ≥ 6  weeks. As far 
as causes are concerned, Table 1 shows the various agents 
inducing urticaria.
Acute urticaria
It is estimated that 12–22% of the general population 
has suffered at least one subtype of urticaria during life 
[2–5], but only a small percentage (estimated at 7.6–16%) 
has AU [6–9]. The age group studied may be important 
because AU seems more common in very young children, 
often linked to infections [10]. In the adult population 
there is a female preponderance (about 60%), while this 
gender difference is less evident in children [11–13]. AU 
is classified as idiopathic in 30–50% of cases [7, 14, 15]. 
An association with respiratory tract infections can be 
present in children and adults, in the latter being impor-
tant to distinguish the role of infection from that of the 
drug to treat it [16, 17]. Drug-induced urticaria, espe-
cially concerning Non steroidal anti-inflammatory drugs 
(NSAIDs), can be commonly observed in elderly people 
[18]. Overall, drugs are reported as cause of AU in 9.2–
27% of cases, antibiotics, NSAIDs and Angiotensin Con-
verting Enzyme (ACE)-inhibitors being reported as most 
commonly associated to AU [19, 20]. Often the mecha-
nism underlying the reaction is not IgE-mediated. Also, 
food allergy may be clinically expressed as AU, in chil-
dren the food most frequently responsible is cow’s milk 
[8]. Food induced AU is mostly IgE-mediated and thus 
the symptoms are of the immediate type, occurring from 
few minutes to 2 h from ingestion. In a variant, AU may 
develop only when physical exercise is performed 2–3 h 
after the contact with the causative food.
The diagnosis of urticaria may be complicated by the 
heterogeneity of its phenotypes. The diagnostic work-
up must start with an accurate clinical history defin-
ing the trait, the duration in order to distinguish acute 
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Table 1 Types of urticaria and causative agents
Type of urticaria Causative agent
Allergic Foods, drugs, Hymenoptera stings
Spontaneous urticaria Unknown
Inducible urticaria Dermographism
Cold
Heat
Sunlight
Pressure
Vibration
Contact
Colinergic
Aquagenic
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from chronic forms, and the possible causative factors 
[1, 21]. Table  2 summarizes the main information to 
obtain according to guidelines [22, 23]. The next step is 
an objective evaluation that assesses the appearance of 
the elemental lesions (wheals and/or angioedema) and 
the absence of signs suggestive of an inflammatory nature 
of urticaria (vasculitis, polymorphic erythema, etc.) In 
the latter case, especially if the individual lesions per-
sist for more than 24  h, the patient should be referred 
to dermatological observation. In the absence of appre-
ciable manifestations at the time of the visit it is very 
useful to reproduce the dermographism, by stroking a 
blunt tip on the patient’s back, to highlight the appear-
ance of a typical linear stroke detected along the site of 
mechanical action. Another important aspect is the gen-
eral state of health and the quality of life (QoL) perceived 
by patients with chronic urticaria is comparable with that 
of patients with chronic coronary artery disease. How-
ever, a validated QoL questionnaire is currently available 
and developed exclusively in patients with CU [24, 25]. 
To establish the urticaria activity, a score can be calcu-
lated according to objective assessment of given items, as 
reported in Table  3. Subsequent diagnostic procedures 
depend strictly on what is highlighted in the clinical his-
tory. In case of short-onset urticaria, if an allergic origin 
is suspected (from food, drugs, hymenoptera stings), it is 
important to perform allergy testing with the appropriate 
techniques and materials, including skin tests, (prick test 
or intradermal test), specific IgE measurement, provoca-
tion test with suspected drugs or foods [26]. When multi-
ple positive tests are observed, the modern techniques of 
component resolved diagnosis (CRD) are indicated [27], 
that may discriminate primary (genuine) sensitizations 
from cross-reactions. 
In isolated angioedema, particularly when recurring 
from years and persisting over 24  h despite corticoster-
oid treatment, a differential diagnosis with hereditary or 
acquired angioedema must be performed by the level of 
C4 and the quantitative and functional measurement of 
C1-inhibitor [28].
Chronic inducible urticaria
The responsibility of a given causative factor defines 
the group of chronic inducible urticaria (CIU), which is 
characterized by the occurrence of wheal or angioedema 
induced by stimuli including cold, heat, dermogra-
phism, pressure, vibration, sunlight and water and rep-
resent 20–35% of chronic urticaria. Contact, cholinergic 
and aquagenic urticaria are not included in this group, 
because the triggering factor is not physical
There are some characteristics that are shared in the 
various forms of inducible urticaria:
(1) the clinical manifestation develops only after an 
adequate stimulus and is regularly reproduced by it; (2) 
usually the latency time varies from a few minutes (e.g. 
cold urticaria) to 3–12  h (e.g. pressure urticaria); (3) in 
general, the single episodes last for about 30–60  min 
(with the exception of pressure-delayed urticaria) and the 
symptoms are localized at the stimulus site; (4) after the 
regression of the lesions without leaving any relic, there 
is a refractory period that is variable, depending on the 
nature of the stimulus (but generally lasting 24–48  h), 
probably linked to the exhaustion of chemical media-
tors [21, 29]; (5) the coexistence of two or more forms of 
inducible urticaria is quite common in the same patient 
[6, 30, 31].
In diagnostic work-up, the aspects of critical impor-
tance are clinical history, because the suspicion of an 
Table 2 Questions to  assess by  history in  patients 
with urticaria
1 Time of the first onset of urticaria
2 Frequency of symptoms and duration of the single wheal
3 Circadian variations
4 Appearance on weekends, holidays or trips abroad
5 Size, shape and distribution of wheals
6 Associated angioedema
7 Concomitant subjective symptoms (itching, burning, pain, etc.)
8 Familiar history of urticaria and atopy
9 Previous or concomitant diseases (allergic, infective, gastroentero-
logical, psychiatric)
10 Surgical implants or events during surgery
11 Potential triggers (physical exercise, physical agents, foods, occa-
sional drugs, etc.)
12 Concomitant medication intake (NSAIDs, vaccines, hormones, 
laxatives, ear or eye drops, suppositories, natural remedies, etc.)
13 Apparent correlation with given food(s)
14 Correlation with the menstrual cycle
15 Cigarette smoking
16 Kind of work and hobbies
17 Stressful episodes
18 Quality of life related to current symptoms
19 Previous treatments for urticaria and its efficacy
Table 3 Urticaria Activity Scale
Score Wheals Itching
0 Absent Absent
1 Mild (< 20 wheals/24 h) Mild (present but not bother-
some)
2 Moderate (20–50 
wheals/24 h)
Moderate (bothersome but 
not interfering with daily 
activities and sleep)
3 Severe (> 50 
wheals/24 h)
Severe (interfering with daily 
activities and sleep)
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inducible urticaria can arise from the location, distribu-
tion and morphology of the lesions, in relation to a spe-
cific triggering factor, and the provocation test, that allows 
us to confirm the diagnosis and to identify the stimulus 
capable to elicit urticaria, followed by the threshold test 
that allows the identification of an individual threshold 
of reactivity to the stimulus [32]. The knowledge of the 
stimulus threshold is useful to the patient for the preven-
tion of urticaria and to the physician for the evaluation of 
the activity of the disease and for the monitoring of the 
therapeutic responses. The provocation test should be 
done before and during therapy. In this regard it is useful 
to remember that before performing the test it is neces-
sary to stop any therapies in place (antihistamines should 
be suspended at least 3 days before the test and systemic 
corticosteroids at least 7  days before). Furthermore, it 
should be noted that, if a period of refractoriness per-
sists after an urticaria manifestation, the provocation test 
should be carried out at least 24 h after the last episode of 
urticaria. Patients for whom there is a strong suspicion of 
an inducible urticaria but who have a negative provoca-
tion test should be retested on skin free from urticaria for 
at least 3 days. It should be emphasized, however, that in 
some patients, despite the presence of a highly suggestive 
clinical history for CIU, the provocation test could give a 
negative result. Moreover, since there is the possibility of 
coexistence in the same subject of multiple subtypes of 
CIU, the provocation test should be performed by exam-
ining all the stimuli that are suspected to be implicated in 
the patient’s CIU [32]. Table 4 summarizes the main fea-
tures of provocation tests.
Chronic spontaneous urticaria
The epidemiological data currently available on CU in 
many cases are deeply discordant and not univocal. The 
main factors involved in the development of this com-
plex framework are the heterogeneity of the studied pop-
ulations and of the degree of correspondence between 
the characteristics of each patient sample and those of 
the general reference population, the heterogeneity of 
the diagnostic criteria used [21, 33], and the discrepan-
cies between studies conducted within or outside ter-
tiary referral centers [34] for the diagnosis and therapy of 
immunological and/or dermatological diseases. Therefore, 
if recent estimates suggest that the prevalence of CU in 
the general population is 0.5–1% [35], there is no definite 
data on the prevalence and annual incidence of spontane-
ous CU (which includes about 50–75% of cases of CU [4, 
36–39]. A recent Italian study, based on the consultation 
of a national registry, which uses the ICD-9-CM classifi-
cation system (International Classification of Diseases, 9th 
Revision, Clinical Modification), reports a prevalence of 
chronic spontaneous urticaria (CSU) of 0.02% to 0.4% and 
an incidence of 0.1–1.5 cases/1000 inhabitants/year [40].
CSU is more common in females (72.7% of cases, 
according to the ASSURE-CSU study, still ongoing [41]), 
which is comparable to that observed in most autoim-
mune diseases [35, 41, 42]. Not surprisingly, the autoim-
mune pathogenesis forms make up about 50% of the total 
number of cases of CSU [43]. The average age of onset is 
in the fourth-fifth decade of life, although all age groups 
can be affected [4, 41]. Unlike other immune-mediated 
pathologies, CSU resolves over 6  months in 50–71% of 
patients [4, 38]. However, in 10% of cases it may persist 
for years and require the use of more aggressive therapeu-
tic regimens [38, 44]. As to pathogenesis, CSU is consid-
ered a multifactorial pathology, into which endogenous 
and exogenous factors contribute. Among the endoge-
nous factors some predisposing Human Leukocyte Anti-
gens (HLA)s have been identified, such as the HLA allele 
DRB1* 04 (coding for HLA DR4) and the allele DQB1* 
0302 (coding for HLA DQ8) [45]. Among exogenous fac-
tors, it is known that some bacterial infections (e.g. Heli-
cobacter pylori, Mycoplasma pneumoniae) or parasitic 
infections (e.g. Giardia lamblia, Anisakis simplex) are 
associated with the development of CSU. Some foods 
(particularly alcohol, spicy foods) and drugs (e.g. NSAIDs) 
or even physical or psychic stress, can be identified as 
causative agents and triggers of urticarial eruptions. 
However, in a high percentage of cases (55–70%), CSU is 
defined as idiopathic because the causes remain unknown 
[46]. A particular variant of CSU is represented by the 
“chronic autoimmune urticaria”. This form is defined by 
the presence in serum of IgG autoantibodies directed 
against the α-subunit of the high affinity receptor for 
the crystallizable fragment of IgE (anti-FcεRIα) or, more 
rarely, IgG anti-IgE. These autoantibodies were found in 
35–40% and 5–10% of patients with CSU, respectively 
[45]. The possibility that some subtypes of CSU may rec-
ognize an autoimmune pathogenesis is supported by 
association with other autoimmune diseases (e.g. rheu-
matoid arthritis, vitiligo, type 1 diabetes mellitus, Hashi-
moto’s thyroiditis), from the combination with the HLA 
DR4 haplotype (which predisposes to diseases such as 
rheumatoid arthritis and autoimmune thyroiditis) and the 
good response of some patients to immunosuppressive 
therapies [42]. Patients with CSU often have non-organ-
specific markers of autoimmune disease, such as rheu-
matoid factor positivity and the presence of antinuclear 
antibodies [45, 46]. Some authors have demonstrated the 
formation of direct IgE against autoantibodies such as, in 
particular, thyroperoxidase (TPO) and the native DNA 
(dsDNA). In these cases, the autoantigen would induce 
the activation of mast cells and basophils according to the 
classic activation mechanism. Approximately one-third of 
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patients with CSU have circulating functional autoanti-
bodies. These antibodies induce the release of mediators 
by tissue mast cells, in particular the cutaneous ones, and 
by circulating basophils by cross-linking the FcεRI recep-
tors. BHRA (Basophil Histamine Release Assay) is cur-
rently the gold standard for the identification of functional 
antibodies; however, this method is rather complex, thus 
the Autologous Serum Skin Test (ASST) is currently used 
as the best in vivo test for the identification of autoanti-
bodies (sensitivity: 70%, specificity: 80%). ASST also cor-
relates with disease activity [47].
The pathophysiology of urticaria
Multiple chemical mediators are involved in urticaria, 
often interacting each other in a complex molecular 
network. Chemical mediators can be secreted at the 
systemic or local level following the activation of sev-
eral cells that are resident in the dermis (mast cells) or 
recruited from peripheral blood (basophils, eosinophils 
and other blood cells).
Mast cells have a key pathogenetic role and can be 
activated by different mechanisms [46]. The most well-
known activation mechanism is the contact with an agent 
that induces a hypersensitivity reaction of the I type with 
production of IgE that binds to FcεRI receptors.
A new exposure to the trigger factor induces the recep-
tor cross-linking and the activation of the intracellular 
signaling resulting in mediator’s production. Such mech-
anism can occur in the absence of re-exposure to the 
antigen in the presence of anti-FcεRIα or anti-IgE IgG, 
with a special role for IgG activating the mast cells, that 
belong mainly to the IgG1 and IgG3 subclasses, able to 
trigger the complement cascade with production of C5a. 
This molecule is able to amplify the mast cells response 
by binding to specific receptors present on their surface. 
Immunologically activated mast cells quickly release vari-
ous preformed mediators, including histamine and some 
proteases (triptases, kinases and carboxypeptidases A), 
as well as synthesize and release lipid metabolites such as 
prostaglandins (PG)D2, leukotrienes ((LT)C4 and LTD4) 
and Platelet Activating Factor (PAF), and, ultimately, 
cytokines and chemokines, particularly tumor necrosis 
factor (TNF) α, interleukin (IL)-1, IL-4, IL-6 and IL-13. 
The activation of mast cells can be done by non-canon-
ical way through molecules known as “superallergens”. 
Superallergens are proteins of bacterial or viral origin 
(Staphylococcus A protein, Peptostreptococcus L protein, 
HIV gp-120) or endogenous proteins synthesized by the 
liver during viral infection. These proteins are able to 
bind non-specifically to surface basal cells IgE interact-
ing with a variable region of heavy chains. The binding of 
superallergens with mast cell IgE induces the activation 
of these cells and the secretion of chemical mediators in a 
Table 4 Main provocations tests used for diagnosis of inducible urticaria
a The positive response to the test can rarely vary in terms of location and morphology; possible but rare diffuse or systemic reactions
b Avoid performing the test in case of a consistent medical history, in particular if associated with systemic symptoms
Kind of urticaria Test site Execution method Reading time Positive  responsea
Cold urticaria Volar surface of the forearm Contact with a ice cube in a thin 
plastic bag for 5 min
10′ Localized wheal
Heat urticaria Volar surface of the forearm Contact with a cylindrical container 
filled with hot water for 5 min
10′ Localized wheal
Sunlight urticaria Buttocks Irradiation with 6 J/cm2 of UVA and 
60 mJ/cm2 of UVB
10′ Localized wheal
Vibratory angi-
oedema
Volar surface of the forearm Contact with a flat surface placed 
on a laboratory vortex at a speed 
between 780 and 1380 rpm (aver-
age, 1000 rpm) for 5 min
10′ Changes in the circumference of the 
forearm in 3 points (wrist, central part 
of the forearm and proximity of the 
elbow) before and after the stimulus
Colinergic urticaria Physical exercise (stationary bike or 
treadmill) until sweating or until the 
appearance of skin symptoms
Immediate and 
after 10′
Widespread small wheals
Aquagenic urticaria Side surface of the neck
Upper part of the back
Contact with tablets soaked in warm 
water for up to 40 min for 5 min
Immediate and 
after 10′
Localized small wheals
Contact  urticariab Volar surface of the forearm Contact with the suspected agent for 
30′ (open test)
If negative,
patch test
scratch patch test
prick test
specific IgE in serum
Immediate and 
up to 60′
Localized wheal
Page 6 of 19Nettis et al. Clin Mol Allergy            (2020) 18:8 
way that is similar to that induced by the classic allergens 
[48].
The pathogenic role of basophils is not yet fully clari-
fied. Some studies demonstrated a significant decrease of 
the number of basophils in peripheral blood of patients 
with CU in active phase and a correlation between the 
basophils decrease and the severity of symptoms [45]. 
Basophils of patients with CSU express higher levels of 
substance P, a neuropeptide closely associated with the 
development of vasodilation and pruritus [49]. Baso-
phils in CSU not only show changes in numbers, but also 
have an altered function [50]. Basophils from patients 
with CSU are less responsive to activation with anti-
IgE antibodies and C5a. This is probably the result of a 
receptor desensitization process that occurs particularly 
in patients in whom the presence of auto-antibodies has 
been demonstrated.
Also eosinophils, despite they are frequently observed 
on biopsies from patients with CSU, have an uncertain 
role. The observation that many patients with CSU pre-
sent serum antibodies directed against the low affin-
ity receptor, which is present at high concentrations on 
eosinophils (anti-FcεRII/CD23) supports their patho-
genic role. These antibodies induce the release of major 
basic protein (MBP) which activates mast cells and 
basophils [50]. Eosinophils also represent the main cell 
responsible for the activation of the coagulation cas-
cade in patients with CSU as the primary source of tis-
sue factor (TF), which in turn would activate mast cells 
by binding to the protease activating receptor-2 (PAR-2 
receptor). It has been observed that patients with CSU 
have higher mean levels of factor VIIa, D-dimer, F1 + 2 
fragment and fibrin degradation products than con-
trols and that these levels correlate with disease severity 
[51]. Thrombin levels are also increased, but there is no 
greater tendency to thrombotic events or alteration of 
coagulation parameters. Thrombin would activate mast 
cells by binding to the PAR-1 receptor [52].
Concerning other cells, in lesion biopsies a perivenu-
lar infiltrate of lymphocytes is generally found, predomi-
nantly CD4+. Cytokines of T helper 2 origin were found 
in the lesions, such as IL-33 and IL-25. High levels of IL-4 
were detected in the serum of patients with CSU. The 
lymphocyte response in the CSU cannot be attributed to 
a specific type T helper (Th)1 or Th2 and some authors 
assume that the lymphocytes infiltrating the lesions actu-
ally have a Th0 profile [53]. Increased levels of IL-17, 
IL-23 and TNFα were also found in serum of patients 
with CSU, demonstrating a possible pathogenic role of 
Th lymphocytes 17 [54]. Finally, among the cells involved 
in the pathogenesis of CSU, platelets could play a key 
role in the sequence of events involved in both inflam-
matory and coagulation processes. Some studies claim 
that the increase in their number, mean corpuscular vol-
ume, and some activation/aggregation parameters would 
be directly correlated with the clinical severity and the 
degree of autoreactivity [55].
In any case, the pathogenic mechanisms described 
above have as final results the release of mediators, 
with a primary role for histamine, which is the main 
mediator responsible for increased vascular perme-
ability. There are four subtypes of histamine recep-
tors, all of type G protein-coupled receptor (GPCR), 
but H1 seems to be the most important in the patho-
genesis of urticaria. The mechanism of action sees the 
activation of the G Protein αq pathway and therefore of 
phospholipase C, which causes an increase in the con-
centration of Ca2+ cytosolic in the vessels of the der-
mis. The latter activates the MLCK (Ca2+/calmodulin 
(CaM)—dependent Myosin Light Chain Kinase) trig-
gering the contraction of the actin-myosin system with 
cell retraction. The reactions triggered downstream of 
the H1 receptor are numerous and, in particular in the 
endothelial cells, there is an activation of several MAP 
Kinases, all determining an alteration of the system of 
intercellular junctions (tight and adherens junctions), 
with gaps formation and consequent increase in ves-
sel permeability. The amount of histamine present in 
the lesions correlates with the disease activity. How-
ever, histamine is not the only mediator involved in 
the pathogenesis of CSU. Serum tryptase levels were 
higher in patients with CSU compared to controls both 
in phase of quiescence and in acute phase [56]. Some 
studies have focused attention on the endothelium and 
on the expression of vasoactive molecules and endothe-
lial adhesion.
In the serum of patients with CSU, higher levels 
of VCAM1, ICAM1 and CCL5/RANTES have been 
found: these molecules could have the role of markers of 
endothelial dysfunction and be implicated in the patho-
genesis of CSU. However, their serum levels do not seem 
to correlate with disease activity nor with the severity of 
the manifestations [57].
Recently, the Vascular Endothelial Growth Fac-
tor (VEGF) and the Calcitonin Gene-Related Peptide 
(CGRP) have been observed in the lesions of the patients 
with the highest levels of vasodilatory factors [58, 59]. Of 
interest, VEGF is also an important vasodilator mediator, 
through the production of nitric oxide (NO). VEGF lev-
els are increased in the plasma of patients with CSU and 
these levels correlate with disease severity.
Some metalloproteinases (MMP-9) and extracellular 
matrix degradation products (Endostatin and Throm-
bospondin 1) are detectable in sera from patients with 
CSU at higher concentrations than controls. IL-31 is a 
cytokine produced by different cell types, which has been 
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proposed to be involved in various chronic skin diseases 
(atopic dermatitis, allergic contact dermatitis, nodular 
prurigo. IL-31 would also play an important role in the 
pathogenesis of CSU, particularly in determining pruri-
tus. This symptom represents in some patients the pri-
mum movens for the appearance of hives in the forms of 
dermographic urticaria [60].
Bradykinin is a mediator with potent vasodilating and 
vasopermeabilizing action, produced by the high molec-
ular weight quininogen due to the action of callicrein. 
The cellular effects of bradykinin are mediated by the 
activation of two receptors (B1 and B2) capable of acti-
vating nitric oxide synthase with release of NO. The role 
of bradykinin in the pathogenesis of CSU has not yet 
been sufficiently investigated, although it is known its 
effect of induction of wheal after subcutaneous injection 
and its pathogenic role in various inflammatory diseases 
of allergic interest (angioedema, rhinitis, asthma) [61].
Still largely unknown are several plasma factors, often 
generically identified as Histamine Releasing Factors 
(HRF). The HRFs include both high molecular weight 
molecules (probably immunoglobulins) and low molecu-
lar weight molecules (< 30kD) capable of activating mast 
cells bypassing the classical activation path represented 
by the FcεRI-IgE axis [62].
Impact of urticaria on quality of life
The available literature shows that urticaria is more than 
a troublesome symptom. Patients with urticaria, when 
compared to healthy subjects or patients suffering from 
other diseases, have a significantly reduced health related 
quality of life (HRQoL) score. Such score, as expected, is 
lower than in healthy subjects, regardless of age, duration 
of disease, or the presence or absence of angioedema [63]. 
However, several studies have confirmed that urticaria 
significantly affects the well-being and HRQoL of patients 
[63, 64]. In particular, a study compared the HRQoL of 
patients with CU with that of patients with coronary 
ischemic disease waiting for by-pass Surprisingly, despite 
more severe limitations in mobility and pain in patients 
with ischemia, in the items related to energy, social iso-
lation and emotional reactions, the scores of the two 
groups were almost overlapping [65]. Globally, emerges a 
picture that highlights that this pathology has an impact 
comparable to more serious diseases. In addition, per-
sonal satisfaction levels are reduced concerning sleep, 
eating behavior, stress resistance, mood, self-esteem, job 
type and professional role [63]. HRQoL in urticaria can 
be assessed by patient reported outcomes (PROs), and 
in particular by validated questionnaire, which include 
generic questionnaires (aimed at evaluating the state of 
health in general, thus allowing the comparison between 
populations of patients with different diseases) and 
specific questionnaires (developed taking into account 
the peculiar characteristics of a given clinical condi-
tion). The most commonly used generic questionnaires 
are the Nottingham Health Profile [24] and the Medical 
Outcomes Study SF-36 [63]. Due to their characteristics, 
these tools allow comparisons between patients suffering 
from different diseases and between patients and healthy 
subjects, but they are not suitable for detecting specific 
problems related to urticaria. The only specific question-
naire for urticaria is the CU Quality of Life Questionnaire 
(CU-Q2oL) [25], developed and validated in Italian, and 
now available in several other languages, which is recom-
mended by the guidelines EAACI/GA2LEN/EDF/WAO 
for the evaluation of HRQoL in urticaria [21]. Recently, 
starting from CUQ2oL, a specific tool was developed 
for the evaluation of HRQoL for single patient use, the 
CU Patient Perspective (CUPP) [64]. It is composed of 
10 questions, structured to make easy the score calcula-
tion, and has an indication of the clinical significance of 
the result obtained. The validation process demonstrated 
how the CUPP meets the criteria of validity and reliabil-
ity, which for questionnaires to be used in the individual 
patient, are much more stringent than those established 
for the tools developed for population studies.
Diagnosis and prognosis
Based on the variety of urticaria types, an accurate his-
tory collection and a general objective examination con-
stitute a valid starting point [66]. The use of laboratory 
tests should be directed to the type of urticaria according 
to a level from 1 to 3 (Table  5). In some forms of urti-
caria, more specific laboratory tests could be useful [33, 
39]. The tests for inducible urticaria were already shown 
in Table 4. Further diagnostic investigations should only 
be considered in subjects suffering from a severe and 
persistent form of urticaria present from prolonged time 
[67–71].
Table 5 Laboratory examination
First level Blood count; Kidney function
Liver function
Indices of inflammation
Total serum IgE
Screening thyroid hormones and autoantibodies to 
thyroid
Second level 
(only if 
history is 
indicative)
Parasitological examination of stools (3 samples)
Autoimmunity
Autologous serum skin test
Anti-Helicobacter pylori antibodies
Skin prick test or specific IgE to Anisakis simplex
Third level D-Dimer dosage and assessment of coagulation
Assessment of complement
Measurement of antibodies to viral agents (EBV, HBV, 
HCV, CMV…)
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Once the patient’s medical history has been collected, 
it will be useful to carry out a general objective exami-
nation with attention to the dermographism (after anti-
histamine treatment has been withdraw from some days). 
Carrying out extensive and costly screening protocols is 
not recommended given the extremely varied nature of 
the triggering causes. For example, immunoreactions of 
the first type (such as food allergy) rarely cause chronic 
urticaria; sometimes the urticaria symptoms could be 
worsened by a toxic effect of some foods, and then a diet 
poor in histamine could give relief to the patient [72]. 
Also, bacterial, parasitic, fungal and viral infections have 
sometimes been associated with the appearance of pom-
foidal lesions (Helicobacter pylori, Streptococcus, Staphy-
lococcus, Mycoplasma pneumoniae, Salmonella, Brucella, 
Borrelia, Chlamydia, Yersinia enterocolitica, herpesvir-
idaae, parvoviridae, caliciviridae, picornaviridae, flavi-
viridae, hepadnaviridae, Anisakis simplex, etc. [65, 72, 
73]. A parasitological examination of feces on 3 sam-
ples, eosinophil count, total IgE assay, anti-Helicobacter 
pylori antibodies can be useful, as well as a prick test for 
Anisakis simplex and the search for IgM to the above-
mentioned pathogens [65, 73, 74]. Sometimes the foci of 
pathogens can be occult and provide a chronic stimulus 
(e.g. dental diseases). On the other hand, screening for 
neoplastic diseases is no longer recommended. A screen-
ing test demonstrating the presence of autoantibodies 
against the high affinity receptor for IgE should be per-
formed (ASST) [75].
Finally, since the coagulation cascade is activated in 
both self-reactive and non-reactive patients, it is of inter-
est that high levels of D-dimer can identify patients with 
more severe pathology; to this end, it would be useful to 
add to the D-dimer assay also an evaluation of the F1 + 2 
fragment of prothrombin, of fibrin and fibrinogen deg-
radation products and of the soluble fibrin monomeric 
complex [76–78].
As to prognosis, CSU is a transitory condition (aver-
age duration 2 to 5  years) and does not endanger the 
patient’s life, even if it is experienced as a disabling con-
dition [79]. In most cases it resolves within a year from 
the onset of symptoms and only around 10% of patients 
are affected by the disease over 5 years [80, 81]. In rare 
cases it goes beyond [82]. However, there are few predic-
tors of response, including genetic factors related to mast 
cell response, hyper-production of histamine and leukot-
rienes [83]. The presence of angioedema, severe forms of 
CU and the presence of antithyroid antibodies have been 
associated with a longer duration of the disease [84].
Differential diagnosis of urticaria
While diagnostic tests of standardized provocation 
are available for the diagnosis of inducible urticaria in 
accordance with international recommendations, the 
spontaneous form should be differentiated from vascu-
litic urticaria, auto-inflammatory syndromes and other 
forms of urticarial dermatitis based on clinical features, 
morphological and histopathological. In chronic spon-
taneous urticaria, the wheals have an asymmetric distri-
bution, they resolve without dyscromic outcome and are 
associated in about 40% of cases with angioedema.
The urticarioid syndromes, on the other hand, are 
extremely heterogeneous and may be localized only in 
the skin or be systemic, but in both cases the clinical pic-
tures are characterized by the presence of atypical, persis-
tent wheals, with bilateral and symmetrical distribution, 
which resolve with residual discolouration, mostly asso-
ciated to other lesions such as papules, vesicles, or bub-
bles rarely associated with angioedema [21].
The most important differential diagnosis of sponta-
neous CU is with vasculitic urticaria, which represents 
5–10% of CU and is characterized by skin lesions similar 
to those of spontaneous urticaria but with histopatho-
logical characteristics typical of cutaneous necrotizing 
vasculitis [85]. Vasculitis concerns the small vessels, par-
ticularly post-capillary venules and there is a form with 
mainly cutaneous involvement called cutaneous small 
vessel vasculitis (CSVV). UV (vasculitic urticaria) that 
can be normocomplementemic (NUV) or hypocomple-
mentemic (HUV) is distinguished by decrease of C1q, C4 
and C3 and HUVS or systemic vasculitic urticaria which 
represents the most severe form of HUV [86]. The diag-
nosis of HUVS is defined by two major criteria: presence 
of urticaria, angioedema or both for at least 6  months 
and hypocomplementemia, and two of the following 
minor criteria: dermal venulitis, arthralgia, moderate glo-
merulonephritis, uveitis or episcleritis, recurrent abdom-
inal pain. In vasculitic urticaria, the wheals have different 
shape and size, widespread to the whole cutaneous area 
without a preferential localization, and they persist for 
more than 24  h with itch, often burning or pain, but 
sometimes asymptomatic. The erythema is intense, it can 
regress to diascopy highlighting at the center of the lesion 
petechiae punctuated and ecchymotic shades [85, 86].
Vasculitic urticaria is mostly idiopathic but some-
times drugs such as anti-folate, antidepressants, cimeti-
dine, or physical stimuli like cold, and sun exposure are 
involved. It may present as a manifestation of a systemic 
pathology and in particular of connective pathologies 
such as systemic lupus erythematosus (SLE), paraneo-
plastic dermatomyositis, systemic sclerosis, or be part 
of systemic vasculitis such as Wegener’s granulomatosis 
or Churg-Strauss syndrome [87]. Moreover, it can follow 
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infections such as acute or chronic viral hepatitis and, in 
some cases, it may be the paraneoplastic manifestation 
of hemolymphopathies such as non-Hodgkin B cell lym-
phoma or myeloma [86].
The pathogenetic mechanism underlying the pathology 
is the formation, by antigens currently unknown, of anti-
gen–antibody complexes that are deposited on the vessel 
wall, trigger the complementary cascade with subsequent 
activation of the mast cells, recruitment of neutrophils 
and vascular damage. Cutaneous biopsy and histological 
examination with direct immunofluorescence are neces-
sary for diagnosis.
If a patient with recurrent wheals reports osteo-artic-
ular pain, unexplained fever and general malaise an 
auto-inflammatory syndrome, that may be hereditary or 
acquired, should be suspected. Auto-inflammatory syn-
dromes are a group of monogenic disorders in the genes 
that regulate the innate immune response, resulting in 
an aberrant activation of mediators and in particular the 
IL-1 pathway. Most of them are associated with rash, 
fever in some cases periodic, but may be unpredictable 
over time without evidence of neoplastic tumor or auto-
immune diseases, arthritis, elevation of inflammation 
indices, abdominal pain, amyloidosis, myalgias and neu-
rological signs. A detailed description of these syndromes 
goes beyond our objectives and will be limited to the 
forms in which urticaria lesions such as cryopyrin-associ-
ated periodic syndrome (CAPS) and Mediterranean fam-
ily fever are more frequently present. CAPS are a group 
of inherited autoinflammatory syndromes that represent 
the clinical spectrum of different mutations of the CIAS1 
gene (cold induced autoinflammatory syndrome) that 
encodes a protein called cryopirine (NALP3), a compo-
nent of the inflammatory agent that activates IL-1alpha 
when the cell receives the danger signal. CAPS include 
the Muckle-Wells syndrome (with urticaria, amiloidosis 
and deafness), the chronic infant with neurologic, cuta-
neous and articular (CINCA) involvement, the autoin-
flammatory cooling syndrome with papillary orticarioid 
lesions after cold exposure accompanied by systemic 
symptoms and with a negative ice cube trigger test [86].
The Mediterranean family fever affects the populations 
originating in the Mediterranean more frequently and is 
associated with a mutant pirine with functional impair-
ment and activation of IL-1beta. The urticaria lesions 
present in this syndrome are persistent, often bilateral, 
symmetrical, but there may also be macular, papulose 
and purpuric lesions accompanied by burning and always 
with systemic symptoms. [86].
Orticarioid dermatitis was recently defined to describe 
patients with a peculiar pattern of hyperreactivity. It 
mostly affects adult patients aged 60 years of age or older, 
with urticaria and eczematous lesions associated with 
intense, bilateral and symmetrical pruritus with localiza-
tion to the trunk and root of the limbs and have a dura-
tion of even weeks. Histological examination shows an 
eczematous reaction with minimal epidermal spongiosis, 
papillary dermal edema and a superficial perivascular 
infiltrate of lymphocytes with eosinophils. The etiol-
ogy is uncertain even though in some cases it has been 
attributed to a reaction to drugs, antihistamines are not 
effective, and a short corticosteroid treatment leads to 
non-definitive remission since the dermatitis can relapse 
[87].
Drug exanthematic reactions are frequent, occurring 
after a few days. Although a maculopapulotic rash with 
erythema initially on the trunk and upper limbs is the 
most frequent form, the lesions may also be intense with 
red, persistent orticarioid lesions with bilateral and sym-
metrical localization and tendency to confluence and 
residual pigmentation associated with mild itching [87].
Cutaneous mastocytosis, previously called urticaria 
pigmentosa, is the most common clinical picture of mas-
tocytosis that can mimic urticaria. It concerns pediatric 
or adult patients with red-brownish macules and pap-
ules which become apparent with rubbing (Darier’s sign), 
with the main site of the trunk and limbs. In pediatric age 
there may be a urticaria rash with persistent lesions also 
localized in the face, spontaneous or caused by rubbing, 
heat or sun exposure. The number of injuries is variable 
but does not correlate with the risk of systemic involve-
ment. In half of the patients flushing appears and synco-
pal or anaphylactic episodes can occur. In adults, rarely 
in children, there may be an asymptomatic involvement 
of the bone marrow. The diagnosis is clinical and histo-
logical with possible recourse to immunohistochemistry 
for the count of the mast cells. The serum tryptase assay 
(< 20 ng/ml) is the most important parameter for screen-
ing patients with possible systemic involvement and for 
their follow-up. The prognosis depends on the age of 
onset and is better for pediatric forms while in adults it is 
possible an evolution towards a systemic mastocytosis in 
a percentage ranging from 3 to 30%. Also, in the systemic 
form there may be episodes of urticaria-angioedema but 
always associated with other systemic symptoms of the 
gastro-intestinal, respiratory, cardiological system [88].
In conclusion, urticaria lesions may appear in a variety 
of skin or systemic diseases.
The clinical-evolutionary criterion is fundamental for 
the differential diagnosis since the lesions of the urticaria 
syndromes are predominantly bilateral, symmetrical, are 
persistent and often resolve with dischromic outcomes, 
are often associated with different skin lesions and sys-
temic symptoms.
The clinical-pathological correlation with biopsy and 
histological examination is the other element that is 
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necessary and in some cases indispensable for a correct 
classification.
Management of urticaria
The management of urticaria must be faced considering 
in each patient essentially two aspects, the first related to 
the identification and elimination of the causes and trig-
gers, the second concerning the effective treatment of 
symptoms. To treat the patient by avoiding the trigger-
ing cause would be the best option, but often in CSU this 
is not possible because the triggering factor is not recog-
nizable, while it may be possible in the rare cases of IgE-
mediated urticaria and partly in the forms induced by 
physical stimuli. The clinical classification in the various 
subtypes is important for a correct diagnostic and thera-
peutic approach. The therapy has the role of reducing the 
release of mediators and the effect that these exert on the 
target organs and to induce tolerance.
The severity of clinical manifestations and the nature 
and strength of the stimulus, which causes and perpetu-
ates the symptoms, are different in individual patients 
and, for example, it is always necessary to evaluate the 
environmental situation in the inducible forms, such as 
hot or cold [21, 89].
Identification and elimination of triggers
Identifying the causes is not easy, because often more 
stimuli can be associated in the same patient. In case of 
remission after the elimination removal of the suspect 
agent, only the recurrence of symptoms in the presence 
of the same agent can lead to the recognition of the cause, 
thus excluding an accidental factor.
Among drugs, antibiotics and NSAIDs are often con-
sidered to cause urticaria. When their responsibility is 
suspected, they must be avoided or replaced to prove 
their actual responsibility. Drugs may also aggravate pre-
existing urticaria [90]. Concerning infections, the most 
frequently suspected are dental and urinary infections, 
but there is no evidence on their role; as to Helicobacter 
pylori, contrasting data were reported about the possibil-
ity to resolve urticaria by effective treatment of the infec-
tion [91].
Food-IgE mediated allergy is rarely associated with 
chronic urticaria, but if a food allergen is identified as 
the triggering factor, it must be eliminated from the diet. 
In some patients there may be a reaction related to non-
IgE mediated allergy, but to a hypersensitivity reaction to 
some foods or ingredients, especially additives [92]. The 
new European guidelines show that there is evidence of 
improvement with the removal of pseudo-allergens for 
periods of at least 3–6  months and how the benefit of 
this diet on clinical manifestations begins to emerge only 
after 3 weeks. The benefits achieved are also linked to the 
type of eating habits and the differences between the var-
ious European countries [1, 92, 93].
It is recognized that stressful events can trigger or 
aggravate urticaria, and that urticaria can worsen a pre-
existing stress. Psychological support therapies can be 
considered in addition to the treatment of the disease 
[94].
Pharmacologic treatment of acute urticaria
The therapy of AU and/or angioedema, although strongly 
conditioned by the identification of the cause, is pre-
dominantly symptomatic. The aim of this treatment is 
to reduce the clinical effects of mediators released by 
mast cells and mainly of histamine, using drugs capable 
to exert a competitive blockade of histamine H1 recep-
tors. Second generation antihistamines (SGA) are gener-
ally considered to be first line drugs in both acute and CU 
[21, 95]. Compared with  1st generation anti-histamines, 
they also have anti-inflammatory effects by inhibiting the 
release of cytokines from mast cells and basophils [96], 
have less rapid action but longer half-life (15–20 h) and 
surpass only minimally the blood–brain barrier having 
greater molecular weight, lower liposolubility and greater 
affinity for glycoprotein P. Therefore, the possibility of 
inducing anticholinergic effects (mucosal dryness, con-
stipation, reduction of diuresis), and sedatives effects is 
significantly lower, even in the elderly with cognitive dis-
orders, increased intraocular pressure and benign pros-
tatic hypertrophy. Likewise, the frequency of sedative 
effects from interaction with other drugs (such as analge-
sics, hypnotics, anxiolytics, antidepressants) and alcohol 
is lower. SGA (except cetirizine, fexofenadine, bilastine, 
acrivastine) are metabolized in the liver by cytochrome 
P450. Thus, the simultaneous administration of other 
drugs using the same enzymatic system (such as ketocon-
azole, erythromycin, clarithromycin, rifampicin, itracon-
azole, cimetidine, cyclosporine) can slow the metabolism 
of antihistamines and increase their plasma concentra-
tion [97].
H1 antihistamines of 1st generation, however, can be 
used in patients with anxiousness or with insomnia due 
to nocturnal exacerbations of the skin symptomatology 
or in the onset phases of urticaria. Taking antihistamines 
should be regular (not as needed) and should be pro-
longed for at least 7–10 days after symptom remission.
In cases of inadequate therapeutic response to antihis-
tamines, two different strategies are possible, i.e. increas-
ing the dosage of the antihistamine used up to four times 
the conventional daily dose or the addition of a corti-
costeroid. The first approach [21, 98–100] is not always 
effective, but is generally well tolerated, except for a pos-
sible increase in drowsiness. It is however advisable to 
obtain informed consent from patients.
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The association with a corticosteroid to ensure greater 
control of mediators can be considered in the most seri-
ous cases when the wheals are very large and widespread 
and/or associated with angioedema, and in presence 
of exacerbation of symptoms [21, 101]. In angioedema, 
however, the association is not useful when the symp-
tomatology is due to the release of non-mast cell media-
tors, such as bradykinin. This occurs in hereditary and 
acquired angioedema (often associated with B-cell lym-
phoproliferative diseases), associated with deficiency 
or dysfunction of the C1 esterase inhibitor, or in angi-
oedema induced by ACE inhibitors.
When cutaneous and/or mucosal symptoms are associ-
ated with one or more systemic symptoms (pulmonary, 
cardio-circulatory, gastro-intestinal, neurological), sug-
gesting an initial anaphylaxis, epinephrine should be pre-
scribed [66].
Pharmacologic treatment of chronic spontaneous urticaria
Antihistamines
These drugs are generally administered in a single daily 
dose, in order to minimize nocturnal sedation. Bilastine, 
at a daily dose of 20 mg, levocetirizine (active enantiomer 
of cetirizine) and desloratadine, both administered at a 
daily dose of 5 mg, appear to be more effective antihista-
mines and with less side effects (sedation and interaction 
with other drugs) compared to 1st generation antihista-
mines. Other SGA tested in CSU are cetirizine, fexofena-
dine, loratadine, ebastine and rupatadine. Antihistamines 
do not modify natural history of CVS, but when symp-
toms control is achieved must be progressively reduced 
to indentify the minimal effective dose
If the symptoms are severe or associated with angi-
oedema, the old H1 antihistamines with sedative action, 
such as hydroxyzine (25 to 50  mg/day) and diphenhy-
dramine (25  mg twice a day) may reduce anxiety and 
insomnia. Adding a second H1 antihistamine or an H2 
histamine in patients with little effect of H1 antihista-
mine treatment. However, treatments combined with H1 
and H2 antihistamines or with two different H1 antihis-
tamines do not seem to provide advantages over mono-
therapy. At present, it is preferred to increase the dose of 
a single antihistamine as indicated by the 2017 EEACI/
GA2LEN/EDF/WAO guidelines [1] which propose a 
4-step therapeutic algorithm. The first step is based on 
SGA in once daily administration; is symptoms persist 
after 2 weeks, the second step increases the SGA dosage 
up to 4 times; if symptoms persist after 2–4 weeks, omal-
izumab is added; if symptoms persist after 6  months, 
cyclosporine is added.
Corticosteroids
Treatment with corticosteroids is generally not rec-
ommended in the treatment of CSU. However, there are 
cases of in which in the pathogenesis of the disease medi-
ators other than histamine are involved, such as PAF, leu-
kotrienes and other cytokines, and the perivasal infiltrate 
shows lymphocytes in addition to basophils and eosino-
phils. These cases respond to a short course of corticos-
teroids and are generally refractory to treatment with 
antihistamines [1, 101].
Ciclosporin
Ciclosporin has a direct effect on the release of media-
tors. The efficacy of cyclosporine in combination with 
second-generation antihistamines has been demon-
strated in open-label and double-blind clinical trials [102, 
103]. Its use is possible, off-label, in patients who have 
not responded to antihistamine therapy or to omali-
zumab. However, the use of this drug as a standard CSU 
therapy, because of the risk of side effects is not recom-
mended [104].
Omalizumab
Omalizumab is a humanized monoclonal antibody 
derived from recombinant DNA that binds selectively to 
human IgE [105]. It was initially approved in the USA in 
2003 for the therapy of patients with moderate to severe 
persistent allergic asthma and then in Europe in 2005 for 
the therapy of allergic asthma resistant to conventional 
therapies [106] In 2013 Omalizumab was included in the 
international guidelines as third line for the treatment of 
patients with CSU resistant to antihistamine therapy and 
was subsequently officially approved in 2014, both in the 
United States and Europe, by the drug regulatory agen-
cies [107]. In Italy Omalizumab, at a dose of 300 mg every 
4  weeks, was reimbursed by the Health System from 
August 2015 with the indication of additional therapy in 
the treatment of CSU in adult and adolescent patients 
(aged ≥ 12 years) with response inadequate to treatment 
with antihistamines H1 [108].
Usually the side effects caused by Omalizumab are mild 
or moderate, but like any drug it can have even serious 
adverse effects [109]. The most commonly reported side 
effects are injection site reactions (pain, swelling, itching, 
erythema), headache and (in children), abdominal pain 
and fever. Serious (very rare) side effects include anaphy-
lactic shock and systemic lupus.
Pharmacologic treatment of chronic inducible urticaria
The therapeutic objective consists in the prevention of 
exposure to the triggering factors and on the sympto-
matic treatment in order to obtain complete control 
of the symptoms and clinical signs and to improve the 
patient’s quality of life [1, 21]. The ideal treatment is in 
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fact based on the elimination of the inducing causes, 
detected by the accurate investigation of the patient’s 
clinical history and, if necessary, by appropriate diagnos-
tic tests (Table 4). When the causes are not identifiable, it 
is in any case indicated to eliminate the factors that can 
more easily cause a worsening of urticaria: drugs, food 
additives, foods rich in histamine or its precursors [1]. 
Regarding the symptomatic pharmacological therapy of 
CIU, it is based on the use of drugs able to block mast 
cell mediators (antihistamines H1, antileukotrienes) or to 
inhibit mast cell activation (omalizumab, cyclosporine) 
[1]. Currently no large studies are available on the treat-
ment of the main types of CIU, in fact the therapeutic 
schemes adopted refer to the guidelines for the treatment 
of CSU [1]. According to current guidelines, second gen-
eration H1 antihistamines represent the first line drugs 
for the treatment of CIU. [1]. When clinical response is 
unsatisfactory, the successive steps are similar to that 
for CSU reported above. Of interest, in some cases CIU 
can be treated through desensitization to trigger factors 
[110]. This phenomenon has been described for cold urti-
caria, cholinergic and solar urticaria. Moreover, although 
rarely, the regress can be spontaneous. Table 6 shows the 
therapeutic indications for the main forms of CIU.
Urticaria in children
The prevalence of pediatric urticaria varies between 2.1 
and 6.7% and appears to be influenced by the atopic con-
stitution [111, 112]. In children, gender differences are 
less evident and forms of AU are more common; only in 
20–30% of cases there is an evolution in chronic urticaria, 
i.e. lasting more than 6 weeks [113]. It is not uncommon 
to observe urticaria factitia and contact urticaria, often 
an expression of food allergy in atopic subjects. Choliner-
gic urticaria is most commonly seen in adolescents.
The diagnosis of urticaria in childhood does not pre-
sent particular difficulties and is based on clinical crite-
ria; its clinical presentation is not different from that of 
the adult. In AU, the hives can more frequently assume 
a figurative appearance and hemorrhagic aspects and 
may result in hyperchromic pigmentary outcomes. The 
association with angioedema is possible in 15% of cases 
[114]. Pruritus is the characteristic symptom, however in 
children under 3 years it may be poor or absent. In the 
case of angioedema located in acroposteous sites, a pain-
ful symptomatology may arise at the joints, which may 
mislead the diagnosis towards a form of acute arthritis. 
Other possible symptoms are abdominal pain, diarrhea 
and vomiting. These symptoms may also be present in 
forms of urticaria vasculitis, but in these cases the hives 
persist over 24  h and pruritus can be scarce or absent. 
As in adults, the symptoms and persistence of hives 
can negatively affect the quality of life of children [115]. 
Numerous agents can act as triggers [114, 116]. More 
often than in the adult in the forms of AU it is possible 
to recognize an infectious etiology [117]. Flu, respiratory 
or gastrointestinal symptoms may be present 1–2 weeks 
before or associated with skin manifestations. A number 
of viral, bacterial, or protozoal agents have been identi-
fied as possible causative agents [113, 117]. The second 
cause of AU is represented by drugs (antibiotics and 
NSAIDs). However, some studies have shown that chil-
dren often tolerate suspected drugs as triggers [118].
In case of repeated episodes of AU, a food etiology 
should be suspected, that must be further researched and 
confirmed through the compilation of a diary (appear-
ance of symptoms less than an hour after ingestion of a 
food) and a careful elimination diet. However, food aller-
gies seem to be present in less than 7% of cases of urti-
caria [1]. The pathogenesis due to immune complexes 
or autoimmunity seems infrequent in pediatric age 
[119–121].
The management of urticaria in children is sub-
stantially similar to that in adults, as underlined in 
guidelines and recent reviews [1, 21, 121]. In AU micro-
biology assessment is not warranted [1, 21, 22]. Specific 
IgE measurement or skin prick tests are indicated only 
when history is strongly suggestive of food allergy. In 
CU possible inflammatory causes may be investigated 
by blood count with formula, erythrocyte sedimenta-
tion rate and C-reactive protein. ASST is not indicated in 
pediatric age because it does not help in identifying the 
causes and does not predict the severity or duration of 
urticaria [1, 21]. Also the search for autoantibodies (anti-
thyroid, anti-transglutaminase, antiendomisium, etc.) is 
justified only in presence of an history clearly suggesting 
such etiology. All variants of CIU must be assessed by 
the appropriate tests according to the specific physical. 
A skin biopsy is justified only in presence of suspected 
vasculitis. Pediatric urticaria seems to have a favorable 
course, with no associations with severe diseases. Recent 
studies reported remission of urticaria in 16% of affected 
children after 1 year, 38% after 3 years and approximately 
50% after 5 years [122].
The same treatment algorithm used for adults may 
be applied, although the recommendation is weak and 
based predominantly on a clinical consensus [21]. The 
first treatment line is represented by SGA [1, 21, 22]. 
First generation antihistamines negatively impact REM 
sleep and school learning ability. More frequently than 
in adults they can also cause paradoxical excitation, 
constipation and weight gain [123, 124]. The use of first-
generation antihistamines should be discouraged both 
for these known side effects and for the absence of ran-
domized controlled trials supporting efficacy [21, 114, 
124]. The most studied SGA are cetirizine, levocetirizine, 
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loratadine, desloratadine, which have evidence of effi-
cacy [21, 114, 124]. Cetirizine, because of a different 
metabolism in children, should be administered B.I.D. 
Rupatadine is a SGA with antagonist action against PAF 
receptors, the efficacy of which was confirmed in con-
trolled trials [125]. Recent studies reported good safety 
and tolerability in children also for bilastine [126].
If SGA have no effect in controlling pruritus and urti-
caria, the dose increased up to four times previously 
reported for adults is not validated in pediatric age [1, 21, 
124]. No studies supporting the use of a combination H1 
and H2 antihistamines as well as the use of antileukot-
rienes or ciclosporin are available [127]. If needed, short 
courses of oral corticosteroids at pediatric dosage for 
no more than 10 days can be performed. Omalizumab is 
approved for the treatment of CSU not responding to anti-
histamines in children aged more than 12 years [128, 129].
Urticaria in pregnancy
The elevated estrogen-progestin levels as well as the 
physiological anatomical changes that characterize preg-
nancy have a significant impact not only on the prod-
uct of conception but also on the health of the mother. 
As known, some pathologies such as bronchial asthma, 
can both improve and worsen during these 9  months, 
therefore requiring an often-multidisciplinary approach 
in women who are planning or carrying out a preg-
nancy. Even some skin diseases show a strong link with 
pregnancy. High hormone concentrations are known to 
exacerbate episodes of angioedema in women carrying 
the XII factor mutation. The same hormonal framework 
may be the trigger of complex systemic diseases such as 
SLE which very often has the skin as the first involved 
organ. Actually, urticaria is not a pathology showing dur-
ing pregnancy a greater incidence of both early diagnosis 
and recurrence in women affected already in the pre-con-
ception period [130, 131]. The major problem for patients 
therefore concerns which therapeutic approach should 
be preferred, both in acute and in chronic urticaria, in 
every phase of pregnancy and breastfeeding.
The therapy must at the same time protect the health 
of the fetus from possible iatrogenic damages, especially 
during the first trimester, but also safeguard the well-
being of the mother. It should not be forgotten that urti-
caria has a very significant impact on the quality of life 
and psychological well-being of patients [132], similar 
to that of atopic dermatitis and psoriasis [133]. Moreo-
ver, there are no studies that exclude a potential harm-
ful effect of the high levels of histamine that characterize 
urticaria [21] as well as of the inflammation and poten-
tially the possible alterations of the coagulation cascade 
that can be associated with the chronic forms.
The most important issue, however, is that mothers and 
often even general practitioners perceive the potential 
harmful effects from drugs as more severe and more fre-
quent than those caused by the disease itself [134–136]. 
An indicative figure in this regard is the high percent-
age of pregnant women treated with bronchial asthma 
[137, 138] and therefore at risk of severe complications 
of the fetus [139]. It is therefore important to educate 
physicians and patients about the importance of using 
the right drugs in  situations that make them necessary 
because even a low level of mother’s health can mean a 
low level of health of the child.
Therapy of urticaria in pregnancy
It is important to distinguish between acute and chronic 
forms and to search for possible triggers and etiological 
agents. The symptoms of urticaria may be the expression 
of pathologies that could significantly affect pregnancy, 
such as food allergies as a risk of anaphylactic reac-
tions [21]. In both acute and chronic urticaria, in addi-
tion to the pharmacological approach, it is usually useful 
to suggest the patient to avoid certain drugs such as the 
Table 6 Treatment of chronic inducible urticaria
SGA second generation antihistamines, UV ultra-violet
Kind of chronic inducible 
urticaria
Treatment
Cold urticaria SGA, desensitization to cold by repeated controlled exposures, in selected cases anakinra or etanercept
Heat urticaria SGA, possibly associated with H2 antihistamines, omalizumab, desentitization to heat by repeated controlled exposures
Sunlight urticaria Photoprotective clothing, use of sunscreens, desensitization to UV rays by phototherapy (UVB or UVA), SGA, omali-
zumab, ciclosporin, intravenous immunoglobulins, afamelanotide
Vibratory angioedema SGA, avoidance of vibratory stimulus.
Pressure urticaria SGA, antileukotrienes (possibly in combination), omalizumab
Colinergic urticaria SGA, omalizumab, scopolamine, danazole
Contact urticaria SGA, avoidance of the causative agent
Dermographism SGA up to four daily, omalizumab, ciclosporin
Aquagenic urticaria SGA, better result if associated with PUVA, barrier creams
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NSAIDs [21]. Concerning foods, in pregnancy prescrib-
ing particularly restrictive diets could deprive the child of 
important nutrients and should therefore be done with 
particular caution.
Fortunately, a large part of the drugs available to treat 
acute and CU has proved safe even during pregnancy and 
lactation. The therapeutic algorithm for this particular 
patient population is the same one applied to the general 
population affected by both acute and chronic urticaria, 
as recommended in the European guidelines [21]. In any 
case, the risk–benefit ratio for each drug to be used must 
be evaluated for each patient. During pregnancy, drugs 
must be used with extreme caution. In this regard, Food 
and Drug Administration (FDA) foresees 5 risk catego-
ries, those belonging to categories A and B being consid-
ered safer.
Concerning antihistamines, SGA must be preferred. In 
particular, the only ones with proven safety during preg-
nancy are loratadine and cetirizine, classified by FDA as 
class B drugs. As with SGA in general, they have a low 
secretion in breast milk and can therefore also be used 
during breastfeeding. If it is necessary to use first genera-
tion antihistamines, the safest are chlorpheniramine and 
diphenhydramine, tough their concentration in breast 
milk is higher, leading to a greater risk of sedation of the 
newborn. To date there are no studies demonstrating 
the safety of a possible increase in the dosage of anti-
histamines both before and second-generation during 
pregnancy [21]. Nevertheless, in the international guide-
lines, this therapeutic approach was recently approved, 
even in pregnancy and lactation, which must in any case 
be implemented with extreme caution [21]. Since these 
dosages are off-label, it could be prudent—especially in 
the first trimester of pregnancy—to use antihistamines 
at increased dosage only in selected cases, using short 
cycles of corticosteroid therapy to increase the control of 
urticaria.
Corticosteroid are considered by FDA class C drugs, 
since prolonged use is associated with the risk of intrau-
terine infections and prematurity [140] in addition to the 
well-known side effects such as arterial hypertension and 
diabetes which can influence the course of pregnancy. 
The higher incidence of previously reported cleft palate 
[141] or other congenital defects in women treated with 
steroids even during the first trimester of gestation has 
not been confirmed in a recent review of scientific lit-
erature [142]. The use of corticosteroids for short peri-
ods can be considered relatively safe. The corticosteroid 
of choice is prednisone, since about 90% of the dose is 
inactivated by the placental enzyme 11-beta hydroxylase 
[143]. In fact, EULAR has approved its use in pregnant 
women suffering from diseases such as lupus or rheu-
matoid arthritis [142]. Corticosteroid use can reduce a 
couple’s fertility, because in humans it inhibits the hypo-
thalamic-pituitary–testicular axis and in women it can 
cause alterations in the ovarian cycle.
As far as biologic agents are concerned, Omalizumab 
was promoted to class B drug according to the FDA 
[144]. The use since 2006 in patients suffering from 
severe asthma has allowed numerous retrospective 
observational studies that have confirmed its safety also 
during pregnancy [145]. The case reported in the lit-
erature of pregnant women suffering from CU treated 
with Omalizumab seem to confirm its safety [146–148]. 
Most authors suggest not starting Omalizumab during 
pregnancy but not discontinuing its use during concep-
tion [149]. Nevertheless, in some of the reported cases 
of CU therapy with Omalizumab was performed in the 
gestational age with no report of adverse events or fetal 
malformations. However, it should be remembered that 
the use of this drug should be reserved only for particu-
larly serious cases. In fact the data available thus far are 
very limited, though no adverse effects related to the use 
of Omalizumab in the progeny of women treated with 
this biological drug have been reported [150]. Antileu-
kotrienes, particularly montelukast, during pregnancy 
does not seem to be risky for the health of the fetus [151] 
so that FDA has classified it as a class B drug. The small 
number of studies related to its use in pregnant women, 
however, recommends that its use should be evaluated on 
a case by case basis [152].
For ciclosporin, no withdrawal is required either dur-
ing conception or during gestation, as this drug does not 
appear to reduce fertility [153] and does not cross the 
placenta, this with no teratogenic effects [154]. Neverthe-
less, the hypertensive risk, the embryotoxicity described 
in some murine models, the cases of preterm birth and 
low birth weight also require very prudent and limit the 
use of ciclosporin to particularly severe cases [155].
Conclusions
Urticaria is a term referring to a group of diseases which 
involve the onset of pruritic wheals, angioedema, or both. 
Urticaria may be divided into acute and chronic forms. 
AU is defined as the occurrence of spontaneous wheals, 
angioedema, or both for < 6  weeks. The diagnostic pro-
cedures in patients with AU are fundamentally different 
from those used in patients with CU. The current rec-
ommendations are thus based on a precise formulation 
of the goals and steps in the recommended diagnostics. 
Because an underlying cause is rarely detected, a causal 
and/or curative treatment in not available for the major-
ity of patients. Therefore, symptomatic therapy remains 
the mainstay of treatment. Modern SGA in licensed 
doses are the treatment of the first choice. In patients 
who do not respond adequately to standard dosage of 
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SGA, the dosage should be increase up to four times 
the standard dosage. Patients who fail to respond ade-
quately even to higher dosages of SGA should be given 
omalizumab (anti-IgE). More effective and safe therapies 
should be investigated for patients who do not respond to 
H1-antihistamines or omalizumab.
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